HighTower Advisors
ALNY icon

HighTower Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

HighTower Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-300
Closed -$4K – 2214
2017
Q1 		$4K Buy
+300
New +$13.9K ﹤0.01% 2044

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors's ALNY Position: Q2 2026 in Review

HighTower Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.77% in Q2 2026, selling an estimated $246K and leaving 105,045 shares worth $31.6M. The position accounts for 0.03% of the portfolio, ranked #499.

HighTower Advisors first reported a position in ALNY in Q3 2015 and has held it in 39 quarters since. The position peaked at $50.4M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • HighTower Advisors held 105,045 shares of Alnylam Pharmaceuticals worth $31.6M as of Q2 2026.
  • HighTower Advisors sold 814 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $246K.
  • Alnylam Pharmaceuticals made up 0.03% of HighTower Advisors's portfolio in Q2 2026, its #499 holding.
  • HighTower Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2015 and has held it in 39 quarters since.
  • HighTower Advisors's Alnylam Pharmaceuticals position peaked at $50.4M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.